cisplatin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

596 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT03321539: Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Active, not recruiting
3
216
RoW
CCRT+GP, Adjuvant GP, CCRT+PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/22
12/25
NCT03192644: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Recruiting
3
162
RoW
TAI, TACE, epidoxorubicin and cisplatin and lipiodol, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Sun Yat-sen University
Hepatocellular Carcinoma
12/22
12/24
ChiCTR1900025341: Camrelizumab in combination with gemcitabine plus cisplatin and SBRT for metastatic lesions versus gemcitabine plus cisplatin in the treatment of metastatic nasopharyngeal carcinoma: a prospective, phase III clinical trial

Not yet recruiting
3
138
 
GP+SHR-1210+SBRT ;GP
West China Hospital, Sichuan University; West China Hospital, Sichuan University, West China Hospital, Sichuan University
nasopharyngeal carcinoma
 
 
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Recruiting
3
120
RoW
Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy
Sun Yat-sen University, Chinese Southwest Oncology Group
Nasopharyngeal Carcinoma
01/23
 
NCT02938546: 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study

Not yet recruiting
3
200
RoW
18F-FDG
Shanghai Chest Hospital
Non-small-cell Lung Cancer
01/23
01/23
CHIPOR, NCT01376752 / 2010-023035-42: Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

Active, not recruiting
3
415
Europe
Maximal cytoreductive surgery, HIPEC
UNICANCER
Ovarian Epithelial Cancer Recurrent
01/23
05/25
KEYNOTE-789, NCT03515837 / 2017-004188-11: Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/)

Completed
3
492
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, pemetrexed, carboplatin, cisplatin, saline solution, Normal saline solution
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
01/23
10/23
NRG-GY006, NCT02466971: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Active, not recruiting
3
450
Canada, US
Brachytherapy, Brachytherapy, NOS, Internal Radiation, Internal Radiation Brachytherapy, Internal Radiation Therapy, Radiation Brachytherapy, Radiation, Internal, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-0191, OCX-191, OCX191, PAN-811
National Cancer Institute (NCI), NRG Oncology
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
01/23
09/24
NCT04675983: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated
3
36
RoW
Sintilimab, Tyvyt, IBI308, Ramucirumab, LY3009806, IMC-1121B, Cyramza, Cisplatin, 5-fluorouracil, Oxaliplatin, Capecitabine
Innovent Biologics (Suzhou) Co. Ltd.
Gastric Adenocarcinoma
02/23
02/23
SKYSCRAPER-08, NCT04540211: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Jan 2023 - Dec 2023: Data from SKYSCRAPER-08 trial in combination with tiragolumab for metastatic esophageal carcinoma
Active, not recruiting
3
461
RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Paclitaxel, Cisplatin, Atezolizumab Matching Placebo, Tiragolumab Matching Placebo
Hoffmann-La Roche
Esophageal Cancer
02/23
08/25
RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Hourglass Jan 2023 - Dec 2023 : Submission in US for 1L gastric cancer
Checkmark Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
Checkmark Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
Jan 2022 - Jan 2022: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
Active, not recruiting
3
997
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU
BeiGene
Gastric, or Gastroesophageal Junction Adenocarcinoma
02/23
12/24
CONTINUUM, NCT03700476: Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Active, not recruiting
3
425
RoW
Sintilimab, IBI308, PD-1 antibody, Gemcitabine, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd.
Nasopharyngeal Neoplasms
02/23
01/25
PROOF 301, NCT03773302 / 2018-004004-19: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Checkmark BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Oct 2022 - Oct 2022: BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Terminated
3
48
Europe, Canada, US, RoW
BGJ398, Infigratinib, Gemcitabine, Cisplatin
QED Therapeutics, Inc., Helsinn Healthcare SA
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
03/23
03/23
NCT04255771: A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion

Not yet recruiting
3
200
RoW
Gemcitabine, Cisplatin, Placebos, Placebo
Qinghua Xia,Prof
Chemotherapy Effect
03/23
06/23
ATTLAS, NCT03991403: Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Active, not recruiting
3
228
RoW
Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab, Carboplatin, Paclitaxel, Carboplatin or cisplatin
Samsung Medical Center
Non-small Cell Lung Cancer
03/23
03/24
Oriental, NCT04449861: Durvalumab Plus Chemotherapy in ES-SCLC

Completed
3
166
RoW
Durvalumab plus chemotherapy
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
03/23
03/23
ACTICCA-1, NCT02170090 / 2012-005078-70 / ACTRN12615001283561: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Active, not recruiting
3
789
Europe, RoW
Gemcitabine, Cisplatin, Capecitabine
Universitätsklinikum Hamburg-Eppendorf, Deutsche Krebshilfe e.V., Bonn (Germany), Cancer Research UK, Australasian Gastro-Intestinal Trials Group, Dutch Cancer Society
Cholangiocarcinoma, Gall Bladder Carcinoma
04/24
04/24
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - PDUFA date for FDA approval in adults with locally advanced/metastatic EGFRm NSCLC (based on FLAURA2 trial)
Jan 2022 - Dec 2023: Data from FLAURA2 trial in combination with carboplatin or pemetrexed/cisplatin for 1L EGFRm NSCLC
Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
AstraZeneca
Non-Small Cell Lung Cancer
04/23
06/26
KEYNOTE-A86, NCT04956692 / 2020-002729-27: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting
3
531
Europe, Japan, US, RoW
Pembrolizumab SC, Pembrolizumab IV, MK-3475, KEYTRUDA®, SCH 900475, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-Paclitaxel, Abraxane, Nanoparticle albumin-bound paclitaxel, Carboplatin, Paraplatin, Paraplatin NovaPlus, Cisplatin, Platinol-AQ, Pemetrexed, LY231514, Alimta, Pemetrexed Disodium
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Non-Small Cell Lung Cancer
04/23
10/26
RATIONALE-312, NCT04005716: Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Completed
3
457
RoW
Tislelizumab, Carboplatin /Cisplatin, Etoposide, Carboplatin / Cisplatin, Etoposide
BeiGene
Small Cell Lung Cancer
04/23
12/23
ASTRUM-007, NCT03958890: A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Active, not recruiting
3
489
RoW
HLX10 100 mg in 10 ml Injection, Placebos
Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma
04/23
12/23
ORIENT-31, NCT03802240: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Checkmark Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Checkmark Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Nov 2021 - Nov 2021: Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Checkmark Data from first interim analysis in combination with Byvasda and chemo in EGFR mutated nonsquamous NSCLC
More
Completed
3
492
RoW
Sintilimab, IBI308, IBI305, Pemetrexed, Cisplatin, Placebo1, Placebo2
Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
07/21
06/23
LIBRETTO-431, NCT04194944 / 2019-001979-36: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
261
Europe, Canada, Japan, RoW
Selpercatinib, LY3527723, LOXO-292, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer
05/23
06/26
ChiCTR2000032288: PD-1 antibody plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for patients with PD-L1 negative and EGFR/ALK wild-type advanced or metastatic non-squamous non-small cell lung cancer : an open-label, randomised, multicentre phase 3 trial

Not yet recruiting
3
510
 
Camrelizumab + pemetrexed + carboplatin / cisplatin ;Bevacizumab + pemetrexed + carboplatin / cisplatin
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Clinical Research foundation of Shanghai Pulmonary Hospital
Lung Cancer
 
 
NCT04885270: Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer

Recruiting
3
50
RoW
cisplatin i.p., intraperitoneal cisplatin
West China Second University Hospital
Epithelial Carcinoma, Ovarian, Neoadjuvant Chemotherapy
05/23
03/24
NCT03574324: TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

Recruiting
3
266
RoW
TPF+CCRT, Experimental group, CCRT+PF, Control group
Guiyang Medical University
Locally Advanced Nasopharyngeal Carcinoma
05/23
05/23
NCT04840290: A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Recruiting
3
30
RoW
Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
Tang-Du Hospital
Non Small Cell Lung Cancer
06/23
06/23
NCT04456322: Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Recruiting
3
326
RoW
RT plus Nimotuzumab, RT plus Cisplatin, Cisplatin
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/23
06/25
PIVOT IO 009, NCT04209114 / 2018-002676-40: A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Calendar Jan 2023 - Dec 2024: From trial in combination with nivolumab for first-line muscle-invasive bladder cancer
Completed
3
114
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Radical cystectomy (RC), Bempegaldesleukin, BMS-986321, NKTR-214, Bempeg
Bristol-Myers Squibb, Nektar Therapeutics
Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
06/23
06/23
NCT06212752: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Active, not recruiting
3
378
Japan
Pembrolizumab coformulated with hyaluronidase, MK-3475A, Pemetrexed, Alimta, Cisplatin, Platinol-AQ, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Pembrolizumab, MK-3475, KEYTRUDA, Filgrastim, Pegylated filgrastim
Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer
09/24
05/28
CANTABRICO, NCT04712903: Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Completed
3
101
Europe
Durvalumab, Cisplatin, Etoposide, Carboplatin
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
06/23
06/23
NCT02465736: Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Active, not recruiting
3
610
RoW
Docetaxel, Docetaxel in Arm A, Cisplatin, Cisplatin in Arm A, Radiation, IMRT, Surgery, Esophagectomy, Vinorelbine, Vinorelbine in Arm B, Cisplatin in Arm B
Sun Yat-sen University
Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer
07/25
07/25
2022-002877-27: A clinical trial testing the hormonal drug letrozole alone or in addition to the usual chemotherapy treatment (paclitaxel and carboplatin) in low-grade serous ovarian or peritoneal cancer.

Not yet recruiting
3
450
Europe
Letrozole, Paclitaxel, Carboplatin, Anastrozole, Exemestane, Cisplatin, Docetaxel, Paclitaxel formulated as albumin bound nanoparticles, Film-coated tablet, Concentrate for solution for infusion, Powder for dispersion for infusion, Femara®, Abraxane
Cancer Trials Ireland, NRG Oncology, Friends of Cancer Trials Ireland, Irish Cancer Society
Primary low-grade serous carcinoma of the ovary or peritoneum., A specific type of cancer called low-grade serous carcinoma of the ovary or peritoneum., Diseases [C] - Cancer [C04]
 
 
2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio para comparar furmonertinib con quimioterapia basada en platino para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico

Not yet recruiting
3
375
Europe
Furmonertinib, AST2818, Tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion, Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Carboplatin Hikma 10 mg/mL concentrate for solution for infusion, Carboplatin Bendalis 10 mg/ml Concentrate for solution for infusion, Carboplatin Fresenius Kabi 10 mg/ml, concentrate for solution for infusion, Cisplatin Hikma 1mg/ml concentrate for solution for infusion, Cisplatin Accord 1 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml concentrate for solution for infusion
ArriVent BioPharma, Inc., ArriVent BioPharma, Inc., Shanghai Allist Pharmaceuticals Co., Ltd.
Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide sin tratamiento previo, localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico (RFCE), Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
3
56
RoW
Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Classical Hodgkin Lymphoma
08/23
12/23
NCT04502641: Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial

Recruiting
3
160
RoW
Docetaxel, Taxol, 5-fluorouracil, Cisplatin, Intensity Modulated Radiation Therapy, Platinum
Sun Yat-sen University
Hypopharyngeal Cancer
08/23
08/25
KEYNOTE-A39, NCT04223856 / 2019-004542-15: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Calendar Apr 2024 - Dec 2025: Accelerated approval in US in combination with Keytruda for 1L/metastatic urothelial cancer (based on EV-302 trial)
Calendar Apr 2024 - Mar 2025: Regulatory submission in JP for 1L metastatic urothelial cancer
Calendar Apr 2024 - Dec 2024: Accelerated approval in US in combination with Padcev for 1L/metastatic urothelial cancer (based on EV-302 trial)
Jan 2023 - Dec 2023: Topline data from EV-302 trial in combination with Keytruda for 1L urothelial cancer
Hourglass Jul 2022 - Dec 2022 : Completion of enrollment of EV-302 trial in combination with Keytruda for urothelial cancer
More
Recruiting
3
990
Europe, Canada, Japan, US, RoW
Enfortumab vedotin, ASG-22CE, ASG-22ME, PADCEV, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Gemcitabine
Astellas Pharma Global Development, Inc., Merck Sharp & Dohme LLC, Seagen Inc.
Urothelial Cancer
08/23
09/27
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/)

Checkmark Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Sep 2020 - Sep 2020: Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Checkmark Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
Jul 2020 - Jul 2020: Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
Checkmark Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
More
Active, not recruiting
3
761
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Active, not recruiting
3
201
RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
NRG-HN007, NCT04458909: Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Terminated
3
15
Canada, US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nivolumab, ABP 206, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma, Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8
08/23
08/23
ORIENT-99, NCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Recruiting
3
500
RoW
Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin, Nab paclitaxel, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer
09/26
10/28
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
2023-000036-30: A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma.

Not yet recruiting
3
60
Europe
Cisplatinum, Carboplatin, Doxorubicin, Fluorouracil, Vincristin, Irinotecan, Etopozyd, Nexavar, Gemcitabine, Oxaliplatinum, Concentrate for solution for infusion, Solution for injection, Coated tablet, Concentrate for dispersion for infusion, Cisplatinum Accord, Carboplatin Accord, Doxorubicin-Ebewe, Fluorouracil medac, VINCRISTIN - RICHTER, Irinotecan CSC, Etopozyd Accord, Nexavar, Gemcitabine Strides, Oxaliplatinum Accord
Medical University of Gdańsk, Medical Research Agency
Hepatoblastoma and liver cancer (hepatocarcinoma), Hepatoblastoma and liver cancer (hepatocarcinoma), Diseases [C] - Cancer [C04]
 
 
Lunchbox, NCT02501954: Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Completed
3
48
Canada, US
Cisplatin, Platinol, Carboplatin, Paraplatin, Paclitaxel, Taxol, Radiation Therapy, RT, Irradiation
Women's Cancer Care Associates, LLC
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer
11/23
11/23
PACIFIC2, NCT03519971 / 2017-004397-34: Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Jul 2023 - Dec 2023: Data from PACIFIC-2 trial for advanced NSCLC
Jul 2023 - Dec 2023: Acceptance of regulatory submission for CRT+ NSCLC (based on PACIFIC-2 trial)
Hourglass Jan 2021 - Dec 2021 : Regulatory submission for advanced stage 3 NSCLC (based on PACIFIC-2 trial)
Active, not recruiting
3
328
Europe, Japan, RoW
Durvalumab, MEDI4736, Placebo, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin, Radiation
AstraZeneca
Non-Small Cell Lung Cancer
09/23
03/25
2012-000563-25: Randomized phase III study of gemcitabine and cisplatin (GC) versus high dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder. ETUDE DE PHASE III RANDOMISEE COMPARANT L’EFFICACITE DE GEMCITABINE ET CISPLATINE (GC) VERSUS METHOTREXATE, VINBLASTINE, DOXO-RUBICINE ET CISPLATINE A HAUTE DOSE (HD-MVAC) DANS LE TRAITEMENT PERI-OPERATOIRE DE PATIENTS PRESENTANT UN CARCINOME A CELLULES TRANSITIONNELLES (CCT) DE VESSIE INFILTRANT LE MUSCLE

Not yet recruiting
3
500
Europe
cisplatin, Gemcitabine, methotrexate, vinblastine, doxorubicin, filgrastim, Concentrate for solution for injection, Powder for solution/suspension for injection, Solution for injection
CHU-Hôpitaux de Rouen, Ministry of health
locally advanced transitional cell cancer of the bladder carcinome à cellules transitionnelles (CCT) de vessie infiltrant le muscle, Chemotherapy before or after radical cystectomy of patient with locally advanced transitional cell cancer of the bladder. chimiothérapie pre ou post cystectomie de patients atteints d'un carcinome à cellules transitionnelles (CCT) de vessie infiltrant le muscle, Diseases [C] - Cancer [C04]
 
 
NCT03817970: Cisplatin Disposition and Kidney Injury

Recruiting
3
72
US
Granisetron, Kytril, Ondansetron, Zofran, Palonosetron, Aloxi
University of Colorado, Denver, Memorial Sloan Kettering Cancer Center, Rutgers University, National Institute of General Medical Sciences (NIGMS)
Nephrotoxicity
09/25
12/26
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Not yet recruiting
3
220
RoW
Almonertinib, HS-10296, chemotherapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
10/23
09/24
AddChemo, NCT05764044: Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

Not yet recruiting
3
50
RoW
cisplatin, gemcitabine, Follow-up
Hospital do Coracao, University of Sao Paulo
Cervical Cancer, Cervix Cancer, Cervix Neoplasm
10/23
12/23
ARTFORCE, NCT01504815: Adaptive Radiation Treatment for Head and Neck Cancer

Active, not recruiting
3
268
Europe
cisplatinum, Conventional radiotherapy, Adaptive radiotherapy
The Netherlands Cancer Institute, Karolinska Institutet, Maastricht Radiation Oncology, Institut Catala de Salut, The Christie NHS Foundation Trust, Gustave Roussy, Cancer Campus, Grand Paris, UMC Utrecht, European Union
Head and Neck Cancer
11/23
09/25
ChiCTR1900027112: A randomized, controlled, multi-center clinical trial for albumin-bound paclitaxel plus cisplatin and capecitabine (Nab-TPC) versus gemcitabine plus cisplatin (GP) in patients with metastatic nasopharyngeal carcinoma

Recruiting
3
134
 
Nab-TPC regimen ;gemcitabine plus cisplatin
Sun Yat-Sen University Cancer center; Sun Yat-Sen University Cancer Center, Researcher initiated, Part of the shiyao company
nasopharyngeal carcinoma
 
 
CA017-078, NCT03661320 / 2017-004692-31: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Calendar Jan 2024 - Dec 2024: Data from CA 017-078 trial in combination with chemotherapy for muscle invasive urothelial cancer
Active, not recruiting
3
861
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Gemcitabine, Chemotherapy, Cisplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
04/25
12/27
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
3
364
RoW
Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Locally Advanced or Metastatic Urothelial Carcinoma
11/23
11/25
STAD-1, NCT00526396 / 2006-003995-36: Small Cell Lung Cancer Toxicity Adjusted Dosing Study

Active, not recruiting
3
160
Europe
cisplatin, etoposide
National Cancer Institute, Naples
Small Cell Lung Cancer
12/23
12/23
DOMAJOR, NCT03912389 / 2018-004791-36: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

Recruiting
3
292
Europe, RoW
BCD-100, Pemetrexed, Cisplatin (or carboplatin), Placebo
Biocad
Non-Squamous Non-Small Cell Neoplasm of Lung
12/23
12/23
FOENIX-CCA3, NCT04093362 / 2019-004630-42: Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Active, not recruiting
3
216
Europe, Japan, US, RoW
TAS-120, Futibatinib, Cisplatin/Gemcitabine
Taiho Oncology, Inc., Taiho Oncology Inc
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
06/24
06/24
NAUTICAL, NCT04574960: Neoadjuvant Upper Tract Invasive Cancer Trial

Recruiting
3
14
Canada
Gemcitabine, Gemzar, Cisplatin, Platinol, Carboplatin, Paraplatin
University Health Network, Toronto, Bladder Cancer Canada
Bladder Cancer, Bladder Urothelial Carcinoma
12/25
12/25
NCT06177301: Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Recruiting
3
266
RoW
Tislelizumab combined with GX, Tislelizumab combined with GP
Fudan University
Nasopharyngeal Carcinoma
12/26
12/27
NCT04280822: Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Recruiting
3
400
RoW
Neoadjuvant immunochemotherapy
Henan Cancer Hospital
Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
12/23
03/28
CheckMate 77T, NCT04025879 / 2019-000262-38: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data readout CheckMate-77T trial for peri adjuvant NSCLC
Hourglass Nov 2023 - Mar 2024 : H2 FY’23 - Submission in Japan for neoadjuvant/adjuvant NSCLC based on CheckMate-77T trial
Active, not recruiting
3
482
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS936558, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
07/23
09/24
KEYNOTE 811, NCT03615326 / 2018-000224-34: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Checkmark From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
Jun 2021 - Jun 2021: From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
Active, not recruiting
3
738
Europe, Japan, US, RoW
Pembrolizumab, Keytruda®, MK-3475, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab, Herceptin®
Merck Sharp & Dohme LLC
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
03/24
12/24
HCHTOG1903, NCT04138212: Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer

Recruiting
3
456
RoW
Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma
12/23
12/28
NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
298
Canada, US, RoW
Penpulimab, cisplatin, gemcitabine, placebo
Akeso
Nasopharyngeal Carcinoma
02/25
09/26
NCT05822934: Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer

Recruiting
3
20
RoW
Carboplatin-Gemcitabine Cisplatin-Gemcitabine
Assiut University
Urinary Bladder Cancer
12/23
12/23
NCT03306121: TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Active, not recruiting
3
322
RoW
TPF+CCRT, TPF induction chemotherapy, CCRT+ PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/23
12/26
GEMSTONE-304, NCT04187352: A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Checkmark Topline data from the GEMSTONE-304 trial in 1L metastatic esophageal squamous cell carcinoma
Jan 2023 - Jan 2023: Topline data from the GEMSTONE-304 trial in 1L metastatic esophageal squamous cell carcinoma
Completed
3
540
RoW
CS1001+ Fluorouracil+Cisplatin, Placebo+ Fluorouracil+Cisplatin
CStone Pharmaceuticals
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
10/22
10/22
IPAN study, ChiCTR2100043426: A multicenter, randomized, open-label, phase III clinical trial of Icotinib plus pemetrexed-cisplatin versus pemetrexed-cisplatin as postoperative adjuvant treatment in stage III (N1-N2) non-small cell lung cancer (NSCLC) with EGFR-sensitive mutation

Recruiting
3
155
 
Icotinib Hydrochloride Tablets ;Pemetrexed Disodium for Injection ;Carboplatin Injection ;Cisplatin Injection ;Icotinib Hydrochloride Tablets
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-financing
Non-small cell lung cancer
 
 
KEYSTONE-002, NCT04807673: Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC

Recruiting
3
342
RoW
Pembrolizumab, Keytruda, Paclitaxel, Cisplatin, neoadjuvant chemoradiotherapy
Tianjin Medical University Cancer Institute and Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Ruijin Hospital, Hebei Medical University Fourth Hospital, Harbin Medical University, Liaoning Tumor Hospital & Institute, Shanxi Province Cancer Hospital, Shandong Jining No.1 People's Hospital, Weifang People's Hospital, Tianjin Medical University General Hospital, Shandong Provincial Hospital
Esophageal Squamous Cell Carcinoma
12/23
05/28
NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Recruiting
3
75
RoW
Olanzapine Tablets, Olanzapine, Placebo
Shi Yanxia
Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin
12/23
03/24
SWOG 1815, NCT03768414: Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Active, not recruiting
3
452
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel
SWOG Cancer Research Network, National Cancer Institute (NCI)
Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
10/23
07/24
RATIONALE-310, NCT03967977: Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Recruiting
3
420
RoW
Tislelizumab, BGB-A317, Placebo, Cisplatin, Gemcitabine Hydrochloride, Carboplatin
BeiGene
Urothelial Carcinoma
06/27
06/27
HELEN-009, NCT05242874: Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer

Completed
3
442
RoW
Fosaprepitant , Tropisetron and Olanzapine, Standard antiemetic therapy without dexamethasone, Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine, Standard antiemetic therapy
Henan Cancer Hospital
Chemotherapy-induced Nausea and Vomiting
08/23
08/23
NILE, NCT03682068 / 2018-001883-48: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission in combination with tremelimumab for urothelial cancer (based on NILE trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan (based on NILE trial) in combination with Imfinzi for 1L urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan in combination with tremelimumab for 1L urothelial cancer based on NILE trial
Hourglass Jan 2022 - Dec 2023 : Regulatory submission based on NILE trial in EU in combination with tremelimumab for 1L urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission (based on NILE trial) in combination with Imfinzi for urothelial cancer
More
Active, not recruiting
3
1244
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
AstraZeneca
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
08/24
06/25
Beamion LUNG-2, NCT06151574: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting
3
270
Europe, Japan, US, RoW
zongertinib, BI 1810631, pembrolizumab, Keytruda®, cisplatin, carboplatin, pemetrexed
Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
03/27
05/28
KEYNOTE-671, NCT03425643 / 2017-001832-21: Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/)

Calendar Jan 2024 - Dec 2024: From KEYNOTE-0671 trial for resectable stage IIb or IIIa NSCLC
Hourglass Sep 2019 - Oct 2019 : Preliminary data from trial for advanced solid tumors and genomic instability at ESMO 2019
Active, not recruiting
3
797
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Placebo, Cisplatin, PLATINOL®, Gemcitabine, GEMZAR®, Pemetrexed, Alimta®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/23
06/26
NCT04923906: Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Recruiting
3
624
RoW
Aumolertinib, HS-10296, Placebo Aumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
01/24
01/26
ChiCTR1800020280: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery: A prospective, Parallel Assignment, Randomized Controlled, Open-label, Multicenter, Non-inferiority, Phase III Clinical Trial

Recruiting
3
286
 
Nedaplatin ;Cisplatin
The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University, Self-raised
Cervical cancer
 
 
ChiCTR1900020527: Concurrent Chemoradiotherapy with Nedaplatin Versus Cisplatin in Patients with Stage IIB-IVA Cervical Cancer: A prospective, Parallel Assignment, Randomized Controlled, Open-label, Multicenter, Non-inferiority, Phase III Clinical Trial

Recruiting
3
676
 
Nedaplatin ;Cisplatin
The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, Self-raised
Cervical cancer
 
 
KEYNOTE-A18, NCT04221945 / 2019-003152-37: Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18//ENGOT-cx11/GOG-3047)

Hourglass Jan 2020 - Dec 2020 : From KEYNOTE-782 trial
Active, not recruiting
3
980
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Placebo for pembrolizumab, Cisplatin, Platinol®, Platinol®-AQ, External Beam Radiotherapy (EBRT), Brachytherapy
Merck Sharp & Dohme LLC, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Uterine Cervical Neoplasms
01/25
01/25
NCT03837808: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Recruiting
3
384
RoW
Nimotuzumab, Cisplatin
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
02/24
02/24
RJ-NKTCL-3, NCT06255795: The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma

Not yet recruiting
3
142
RoW
chidamide, anti-PD1 antibody, and pegaspargase, DDGP
Ruijin Hospital
Extranodal Natural Killer T Cell Lymphoma
12/26
12/28
OLYMPIA-4, NCT06230224: A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
3
216
Europe, RoW
Odronextamab, R1979, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, Etopophos, Rituximab, Rituxan, Dexamethasone, Decadron, Cisplatin, Platinol, Cytarabine, Cytosar-U, Gemcitabine, Gemzar
Regeneron Pharmaceuticals
B-Cell Non-Hodgkin Lymphoma (B-NHL)
07/27
07/27
NCT06258811: Neoadjuvant Immunochemotherapy for LAOSCC

Recruiting
3
134
RoW
albumin paclitaxel, cispatin, tislelizumab
Lai-ping Zhong, Sun Yat-sen University, Fudan University, Central South University, Fujian Medical University
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
12/26
12/28
NCT06282211: the Efficacy and Safety of Ondansetron Oral Soluble Pellicles

Recruiting
3
184
RoW
Ondansetron Oral Soluble Pellicles, Aiqisu
The First Affiliated Hospital of Xinxiang Medical College
Nausea and Vomiting
03/24
12/24
KANALRAD, NCT06207981: Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

Recruiting
3
310
Europe
induction chemotherapy (mDCF), Concomitant chemotherapy (Capecitabin + Mitomycin-C), radiotherapy
Federation Francophone de Cancerologie Digestive, Fondation ARCAD
Anal Cancer
02/29
02/30
KEYNOTE-585, NCT03221426 / 2016-004408-76: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/)

Calendar Jan 2024 - Dec 2024: From P3 KEYNOTE-585 trial for patients with gastric and gastroesophageal junction adenocarcinoma
Active, not recruiting
3
1007
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®
Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Cancer
02/24
06/25
KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting
3
115
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®
Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Cancer
02/24
06/25
NCT02639650: Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Recruiting
3
214
RoW
Etoposide, VP-16, actinomycin D, ACTD, Sanamycin, methotrexate, MTX, vincristine, VCR, cyclophosphamide, CTX, Paclitaxel, Taxol, Cisplatin, DDP, Carboplatin, CBP
Weiguo Lv, Shandong University, Huazhong University of Science and Technology, First Affiliated Hospital of Zhongshan Medical University
Gestational Trophoblastic Neoplasms
03/24
03/26
BEATcc, NCT03556839 / 2018-000367-83: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Active, not recruiting
3
404
Europe, Japan, US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Cisplatin/Carboplatin, Paclitaxel
Grupo Español de Investigación en Cáncer de Ovario, Hoffmann-La Roche, ARCAGY/ GINECO GROUP, Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies, MaNGO, NSGO, Japanese Gynecologic Oncology Group, Gynecologic Oncology Group Foundation, AGO Study Group, Apices Soluciones S.L.
Carcinoma of the Cervix, Stage IVB
11/24
11/24
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
3
48
US
Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206
Maximilian Diehn, AstraZeneca
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
04/26
04/28
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
3
593
RoW
PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
02/27
02/30
NCT05805800: Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV

Recruiting
3
238
RoW
5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone
Xingchen Peng
Chemotherapy-induced Nausea and Vomiting
03/24
03/25
NIRVANA-LUNG, NCT03774732: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

Recruiting
3
327
Europe, RoW
Radiotherapy, 3D-CRT or SABR, Pembrolizumab, Chemotherapy, Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed
UNICANCER, National Cancer Institute, France
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
09/26
09/26
NCT05179239: A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Recruiting
3
572
RoW
SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102, Placebo + paclitaxel + cisplatin/carboplatin ± BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cervical Cancer
03/24
05/25
NCT06281964: Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Not yet recruiting
3
327
NA
PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab
Avistone Biotechnology Co., Ltd.
Non-Small-Cell Lung Cancer
01/26
12/26
Neotorch, NCT04158440: Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Checkmark Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Jan 2023 - Jan 2023: Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Active, not recruiting
3
501
RoW
4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab, Cisplatin;, Carboplatin;, Pemetrexed;, Paclitaxel;, Docetaxel, 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
Shanghai Junshi Bioscience Co., Ltd.
Stage II-III Non-small Cell Lung Cancer
03/24
10/24
CheckMate 901, NCT03036098 / 2016-003881-14: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Calendar Jan 2024 - Dec 2024: Data readout from CheckMate 901 trial in combination with Yervoy for cis-ineligible 1L urothelial cancer
Mar 2023 - Mar 2024: Submission in Japan in combination with chemotherapy for 1L urothelial cancer (based on CheckMate-901 trial)
Hourglass Jan 2023 - Dec 2023 : Submission in Japan in combination with Opdivo for 1L urothelial cancer (based on CheckMate-901 trial)
Feb 2023 - Dec 2023: Data readout from CheckMate 901 trial in combination with Yervoy for cis-eligible 1L urothelial cancer
Hourglass Oct 2023 - Oct 2023 : OS and PFS data from P3 CheckMate-901 trial in 1L unresectable or metastatic urothelial carcinoma at ESMO 2023
More
Active, not recruiting
3
1290
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Gemcitabine, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Urothelial Cancer
10/24
06/28
NCT05304468: Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Recruiting
3
380
RoW
IMRT, induction chemotherapy, cisplatin concurrent chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
04/24
04/26
NCT06333821: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not yet recruiting
3
460
NA
Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab, placebo
Biotech Pharmaceutical Co., Ltd.
Cervical Cancer
04/30
04/30
MK-2870-019, NCT06312137: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR)

Recruiting
3
780
Europe, US, RoW
Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel
Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
02/34
10/34
 

Download Options